CRO LakePharma Acquires Blue Sky BioServices
LakePharma, Inc., a provider of integrated solutions covering the biologics contract research organization (CRO) space, has acquired Blue Sky BioServices, a CRO specializing in protein and antibody production and assay services. The combined company will be known as LakePharma and will provide a broad range of protein and antibody-related development services to the pharmaceutical and biotechnology markets. Blue Sky BioServices is a portfolio company of Ampersand Capital Partners and as part of the transaction, Ampersand made an investment into LakePharma to support growth initiatives.
LakePharma now has nearly 100 employees and four facilities located in the key San Francisco Bay Area and Cambridge/Boston biotech hubs. It specializes in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics. Blue Sky Bioservices offers gene synthesis to E. coli, insect and mammalian expressions services, including antibody cloning and production, protein purification, and a range of assay services.
Source: LakePharma